Candel Therapeutics, Inc. (CADL) News
Filter CADL News Items
CADL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CADL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CADL News From Around the Web
Below are the latest news stories about CANDEL THERAPEUTICS INC that investors may wish to consider to help them evaluate CADL as an investment opportunity.
After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer winCandel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for. |
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the closing of its previously announced underwritten public offering of 12,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stoc |
Top Midday DeclinersRepare Therapeutics (RPTX) reported Thursday results from a phase 1 trial of cancer drugs lunreserti |
Sector Update: Health Care Stocks Steady Premarket FridayHealth care stocks were steady premarket Friday, with The Health Care Select Sector SPDR Fund (XLV) |
Candel Therapeutics Announces Pricing of Public OfferingNEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 10,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the pu |
Candel Therapeutics Announces $80 Million Proposed Public OfferingNEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $80 million of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to b |
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary GoalCandel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer. |
Candel Skyrockets 68% On A Potential First-In-20-Years Cancer DrugShares of Candel Therapeutics skyrocketed Wednesday after the biotech company's prostate cancer treatment succeeded in a Phase 3 study. |
Candel Therapeutics Prostate Cancer Therapy Shows PromiseBy Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients. “We look forward to working with the FDA, as a next step, to seek approval to bring CAN-2409 to patients in the U.S., and advance our broad viral immunotherapy […] |
Candel Therapeutics stock up 172% after Phase III prostate cancer successThe company’s stock price soared after its prostate cancer drug CAN-2409, met the primary endpoint in a Phase III study. |